ArticleActa biomaterialia2020
Dual antibacterial drug-loaded nanoparticles synergistically improve treatment of Streptococcus mutans biofilms.
Article in Acta biomaterialia, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 1 synthesis or guideline pooled it, 49 citations in OpenAlex.
- Key virulence genes associated withFrontiers in oral health · 2025Pooled it
- Rationally Designed Zwitterionic Peptides Improve siRNA Delivery of Cationic Diblock Copolymer-Based Nanoparticle Drug-Delivery Systems.ACS applied nano materials · 2026Article
- Biomimetic Deposition of Zn-Doped Calcium Phosphate Coatings on Surface-Activated Ti6Al4V for Multifunctional Implant Interfaces.Journal of functional biomaterials · 2026Article
- Mechanism of Action of Zinc Oxide Nanoparticles as an Antibacterial Agent AgainstBiomolecules · 2025Article
- Reproducible 3D bioprinting ofMicrobiology spectrum · 2025Article
- Polyaspartic Acid-Calcium-Lanthanum Complexes Induce Antibacterial Remineralization of Dentin and In-Depth Occlusion of Dentinal Tubules.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Antimicrobial and Antibiofilm Properties of Hydroxyapatite/Nano-Hydroxyapatite in Preventing Dental Caries: A Systematic Review.European journal of dentistry · 2025Article
- Natural compounds: new therapeutic approach for inhibition ofFrontiers in pharmacology · 2025Review
- Polymer vesicles for the delivery of inhibitors of cariogenic biofilm.Dental materials : official publication of the Academy of Dental Materials · 2024Article
- Exploring the efficacy of in-vitro low-temperature plasma treatment on single and multispecies dental cariogenic biofilms.Scientific reports · 2024Article
- Advances in hybridized nanoarchitectures for improved oro-dental health.Journal of nanobiotechnology · 2024Review
- Carboxymethyl chitosan stabilized AuNPs/ACP nanohybrids in enamel white spot lesions.Frontiers in bioengineering and biotechnology · 2024Article
- Treatment of periodontal disease: does drug delivery matter?Frontiers in bioengineering and biotechnology · 2024Article
- Drug Delivery Approaches to Improve Tendon Healing.Tissue engineering. Part B, Reviews · 2023Review
- Hydrogel-Encapsulated Biofilm Inhibitors Abrogate the Cariogenic Activity ofJournal of medicinal chemistry · 2023Article
- Smart dental materials for antimicrobial applications.Bioactive materials · 2023Article
- Zerumbone Disturbs the Extracellular Matrix of Fluconazole-ResistantJournal of fungi (Basel, Switzerland) · 2023Article
- Effect of Extracts, Fractions, and Isolated Molecules ofAntibiotics (Basel, Switzerland) · 2023Article
- Development of an antibacterial polypropylene/polyurethane composite membrane for invisible orthodontics application.Frontiers in bioengineering and biotechnology · 2023Article
- New Autonomous Water-Enabled Self-Healing Coating Material with Antibacterial-Agent-Releasing Properties.Pharmaceutics · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 2 countries.
Funding
Abstract
Dental caries (i.e., tooth decay), which is caused by biofilm formation on tooth surfaces, is the most prevalent oral disease worldwide. Unfortunately, many anti-biofilm drugs lack efficacy within the oral cavity due to poor solubility, retention, and penetration into biofilms. While drug delivery systems (DDS) have been developed to overcome these hurdles and improve traditional antimicrobial treatments, including farnesol, efficacy is still modest due to myriad resistance mechanisms employed by biofilms, suggesting that synergistic drug treatments may be more efficacious. Streptococcus mutans (S. mutans), a cariogenic pathogen and biofilm forming model organism, has several key virulence factors including acidogenicity and exopolysaccharide (EPS) matrix synthesis. Flavonoids, such as myricetin, can reduce both biofilm acidogenicity and EPS synthesis. Therefore, a nanoparticle carrier (NPC) DDS with flexibility to co-load farnesol in the hydrophobic core and myricetin within the cationic corona, was tested in vitro using established and developing S. mutans biofilms. Co-loaded NPC treatments effectively disrupted biofilm biomass (i.e., dry weight) and reduced biofilm viability by ~3 log CFU/mL versus single drug-only controls in developing biofilms, suggesting dual-drug delivery exhibits synergistic anti-biofilm effects. Mechanistic studies revealed that co-loaded NPCs synergistically inhibited planktonic bacterial growth compared to controls and reduced S. mutans acidogenicity due to decreased atpD expression, a gene associated with acid tolerance. Moreover, the myricetin-loaded NPC corona enhanced NPC binding to tooth-mimetic surfaces, which can increase drug efficacy through improved retention at the biofilm-apatite interface. Altogether, these findings suggest promise for co-delivery of myricetin and farnesol DDS as an alternative anti-biofilm treatment to prevent dental caries.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.